We recently published a list of 10 Micro-Cap Stocks Insiders Were Buying In Q1 2025. In this article, we are going to take a look at where Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) stands against other micro-cap stocks insiders were buying in Q1 2025.
The White House announced Tuesday that Trump’s tariffs would take effect immediately after being unveiled on Wednesday. In anticipation of these “reciprocal tariffs,” which will apply to all countries, the stock market reacted. By Tuesday morning, the broader market index and Nasdaq Composite dropped by about 0.2%, while blue-chip companies lost 0.06%.
Amid ongoing market uncertainty, insider trading often comes under the spotlight. Executive stock purchases can signal optimism, but sales may reflect personal financial decisions or a need to diversify investments. To maintain transparency, executives typically follow pre-arranged strategies, like 10b5-1 plans. While insider trading can offer valuable information, it’s important to evaluate it in the broader context of the company’s financial stability and current market trends.
Our Methodology
Today, we’re focusing on stocks with micro market capitalizations that have seen significant insider buying in the first quarter of the year. Using Insider Monkey’s insider trading screener, we identified companies with market caps under $250 million where at least three insiders purchased shares in the past three months. From this list, we ranked the top 10 stocks with the highest number of insiders making purchases. Stocks that have been recently covered were excluded from our analysis.
Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
With each stock, we note the number of insiders who acquired shares in the first quarter and market capitalizations.
A microbiologist in a lab coat, examining a sample of Gram-positive bacteria.
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP)
Number of insiders buying: 6
Market Capitalization: $8.36 million
Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing antibiotics to treat bacterial infections, with its lead candidate, ibezapolstat, currently in Phase 2b trials for Clostridium difficile infections. The Staten Island, New York-based company also develops ACX-375C, a potential treatment for gram-positive bacteria, including resistant strains like MRSA and VRE. It ranks first among 10 micro-cap stocks insiders were buying in the first quarter of 2025.
During the first quarter, six insiders, including the president and CEO acquired around $170,000 worth of Acurx shares at an average price of $1.02 per share. Currently, the stock trades at $0.38 per share, having lost 53.17% year-to-date and 82.52% over the past 12 months.
For the full year 2024, Acurx reported a net loss of $14.1 million or $0.87 per share, compared to a net loss of $14.6 million or $1.15 per share in 2023. General and administrative expenses reached $8.7 million, compared to $8.5 million in the prior year. The increase was primarily due to a $700,000 increase in professional fees, a $300,000 increase in legal fees, offset by a $600,000 decrease in share-based compensation costs and a $200,000 decrease in insurance costs. Research and development expenses were $5.4 million compared to $6.0 million in 2023. The company ended the year with cash totaling $3.7 million, compared to $7.5 million as of December 31, 2023.
One analyst has given Acurx stock a “Strong Buy” rating, with a 12-month price target of $12.00, reports StockAnalysis.
Overall, ACXP ranks 1st on our list of micro-cap stocks insiders were buying in Q1 2025. While we acknowledge the potential of ACXP our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ACXP but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
